Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells

Mikhail V. Blagosklonny

doi:10.18632/oncotarget.548

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells

Mikhail V. Blagosklonny _

PDF | HTML | How to cite

Oncotarget. 2012; 3:601-607. https://doi.org/10.18632/oncotarget.548

Metrics: PDF 2236 views | HTML 3266 views | ?

Abstract

Mikhail V.Blagosklonny¹

¹ Department of CellStress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA

Received: June 25, 2012; Accepted: June 30, 2012; Published: July 12, 2012;

Keywords: cancer, DNA damaging drugs, side effects, apoptosis, senescence, drug combinations, cyclotherapy

Correspondence:

Mikhail V.Blagosklonny, email:

Abstract

As published recently in Cancer Cell, p53 impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. I discuss that, while treating tumors lacking wt p53, this phenomenon can be exploited to protect normal cells from chemotherapy because all normal cells have wt p53. Also, several therapeutic paradigms can be reassessed, including the role of cellular senescence in cancer therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 548

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Perspectives:

Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells

Abstract